AOR^TM certifie qu'aucun ingrédient non mentionné sur l'étiquette n'a été ajouté au produit. Ne contient ni blé, ni gluten, ni maïs, ni noix, ni produits laitiers, ni soja, ni oeufs, ni poissons, ni mollusques ou crustacés.

Posologie Adulte: Prendre une capsule par jour avec nourriture, ou suivant les recommandations d'un praticien de la santé.

Mise en Garde: Aucune

Applications: Santé de la prostate, Bénéfique pour les os et les articulations

Source: Produit pharmaceutique de synthèse

La capacité du bore à améliorer la santé osseuse est basée sur son soutien du métabolisme favorable du calcium, du magnésium et de la vitamine D. C'est pour ces dernières raisons ainsi que pour plusieurs autres, que le bore pourrait bientôt obtenir la reconnaissance officielle qui le définira comme "essentiel".


References

Zhang Z-F, Winton MI, Rainey C, et al: Boron is associated with decreased risk of human prostate cancer. FASEB J 15:A1089, 2001.

Stacewicz-Sapuntzakis M, Bowen PE, Hussain EA, et al: Chemical composition and potential health effects of prunes: a functional food? Crit Rev Food Sci Nutr 41:251-86, 2001.

Gallardo-Williams MT, Maronpot RR, King PE, et al: Effects of boron supplementation on the morphology, PSA levels, and proliferative activity of LNCaP tumors in nude mice. Proc Amer Assoc Cancer Res 43:77, 2002.

Murmu N, Ghosh P, Gomes A, et al: Antineoplastic effect of new boron compounds against leukemic cell lines and cells from leukemic patients. J Exp Clin Cancer Res 21:351-6, 2002.

Webber MM, Waghray A, Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1:1089-94, 1995.

Nielsen FH: Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. Magnes Trace Elem 9:61-9, 1990.

US Department of Health and Human Services, Surgeon General's report on nutrition and health. Rocklin, CA, Prima Publishing and Communications, 1988.

Hall IH, Rajendran KG, Chen SY, et al: Anti-inflammatory activity of amine-carboxyboranes in rodents. Arch Pharm (Weinheim) 328:39-44, 1995.

Blasko I, Grubeck-Loebenstein B: Role of the immune system in the pathogen- esis, prevention and treatment of Alzheimer's disease. Drugs Aging 20:101-13, 2003.

Penland JG: The importance of boron nutrition for brain and psychological function. Biol Trace Elem Res 66:299-317, 1998.

3-12, 1993Pan XQ, Wang H, Lee RJ: Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res 22:1629-33, 2002.

Vicente MG: Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress. Curr Med Chem Anti-Canc Agents 1:175-94, 2001.

Bai Y, Hunt CD: Dietary boron enhances efficacy of cholecalciferol in broiler chicks. J Trace Elem Exp Med 9:117-132, 1996.

Nielsen FH, Penland JG: Boron supplementation of perimenopausal women affects boron metabolism and indices associated with macromineral metabolism, hormonal status and immune function. J Trace Elem Exp Med 12:251-261, 1999.

Nielsen FH: Boron in human and animal nutrition. Plant and Soil 193:199- 208, 1997.

Effects of dietary boron on cervical cytopathology and on micronucleus frequency in exfoliated buccal cells.
Environ Toxicol. 2007 Feb;22(1):17-25.
Korkmaz M, Uzgoren E, Bakirdere S, Aydin F, Ataman OY.

Recent evidence indicates that boron and borates may have anticarcinogenic properties. In this study, we have investigated the incidence of adverse cytological findings in cervical smears and the micronucleus (MN) frequency in women living in boron-rich and boron-poor regions. Cervical smears were prepared from 1059 women with low socioeconomic status; 472 of the women lived in relatively boron-rich rural areas, while 587 lived in relatively boron-poor regions. The average and standard deviation values for the age of the women screened with the cervical Pap smear test were 41.55 +/- 8.38. The mean dietary intake of boron was 8.41 mg/day for women from the boron-rich regions, and 1.26 mg/day for women living in the boron-poor regions (P < 0.0001). Women from the boron-rich regions had no cytopathological indications of cervical cancer, while there were cytopathological findings for 15 women from the boron-poor areas (chi(2) = 10.473, P < 0.05). Sixty women, 30 from each region, were chosen for evaluating MN frequencies in exfoliated buccal cells. MN frequencies for women from the boron-rich and boron-poor regions were not significantly different (t = -0.294, P > 0.05). Also, there were no significant correlations between age and MN frequency for women from both the boron-rich (r = 0.133, P = 0.48, P > 0.05) and boron-poor (r = -0.033, P = 0.861, P > 0.05) regions. The results suggest that ingestion of boron in the drinking water decreases the incidence of cervical cancer-related histopathological findings. There was no correlation between the pathological findings from the cervical smears and buccal cell MN frequency suggesting that the two study populations were exposed equally to gentotoxic agents. Nonetheless, cervical cancer-related histopathological findings should be validated by other researchers.


Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States).
Cancer Causes Control. 2007 Feb;18(1):71-7.
Barranco WT, Hudak PF, Eckhert CD.

OBJECTIVE: To determine: (1) the correlation of prostate cancer incidence and mortality with groundwater boron and selenium concentrations; and (2) the impact of boron on prostate cancer cell proliferation during co-treatment with alternative chemo-preventative agents, along with boron pre-treatment effects on cell sensitivity to ionizing radiation.
METHODS: For regression analysis, data on prostate cancer incidence and mortality were obtained from the Texas Cancer Registry, while groundwater boron and selenium concentrations were derived from the Texas Water Development Board. Cultured DU-145 prostate cancer cells were used to assess the impact of boric acid on cell proliferation when applied in combination with selenomethionine and genistein, or preceding radiation exposure.
RESULTS: Groundwater boron levels correlated with a decrease in prostate cancer incidence (R = 0.6) and mortality (R = 0.6) in state planning regions, whereas selenium did not (R = 0.1; R = 0.2). Growth inhibition was greater during combined treatments of boric acid and selenomethionine, or boric acid and genistein, versus singular treatments. 8-day boric acid pre-exposure enhanced the toxicity of ionizing radiation treatment, while dose-dependently decreasing the expression of anti-apoptotic protein Bcl-2.
CONCLUSIONS: Increased groundwater boron concentrations, across the state of Texas, correlate with reduced risk of prostate cancer incidence and mortality. Also, boric acid improves the anti-proliferative effectiveness of chemo-preventative agents, selenomethionine and genistein, while enhancing ionizing radiation cell kill.